Skip to content
Research/Peptides/Epithalon (Epitalon)

Epithalon (Epitalon)

Synthetic tetrapeptide bioregulator derived from pineal gland extract. Activates telomerase, extends telomeres, regulates melatonin production, antioxidant. Sequence: Ala-Glu-Asp-Gly.

Intelligence Profile

Research Papers

The available research on Epithalon (also called Epitalon) consists primarily of laboratory studies, with no clinical trials identified in major databases. The evidence comes from a small collection of preclinical investigations examining this tetrapeptide's potential biological effects.

A 2025 review in the International Journal of Molecular Sciences provides an overview of Epithalon as a "highly bioactive pineal tetrapeptide," though specific details about study methodology and findings are not available from the citation alone.

Several laboratory studies have investigated Epithalon's cellular effects:

  • A 2022 study published in Aging examined Epithalon's protective effects against age-related damage in mouse egg cells (oocytes) in laboratory conditions, though sample sizes and specific methodology are not detailed in the available information.

  • Research from 2020 in Molecules explored how the AEDG peptide sequence (Epithalon) might stimulate gene expression and protein synthesis during the formation of new neurons, suggesting possible epigenetic mechanisms. This was conducted using laboratory cell cultures.

  • A 2019 study in the International Journal of Immunopathology and Pharmacology investigated short peptides' effects on stem cell differentiation into neurons, including Epithalon among the peptides studied.

Additional research has focused on:

  • Identification of the AEDG peptide in pineal gland tissue (2017)
  • Comparative studies of peptide levels in rodents with different lifespans (2017)
  • Effects on skin cell function during aging in laboratory conditions (2016)

Important limitations: The available evidence consists entirely of laboratory studies using cell cultures and animal models. No human clinical trials have been identified, and sample sizes for the preclinical studies are not specified in the available abstracts. The research base remains limited, making it difficult to draw conclusions about safety or efficacy in humans.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals before considering any experimental treatments.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.